Redox Homeostasis and Oxidative Stress in Schizophrenia: Glutathione–NMDA–Neuroimmune Convergence and a Hypothesis-Generating Iron–Lipid Redox Extension
Open Access
- 8 August 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7105
Abstract
Schizophrenia is a heterogeneous neurodevelopmental disorder in which genetic liability, developmental exposures, illness stage, treatment, and metabolic or inflammatory comorbidity may shape redox biology. This narrative review evaluates the human and mechanistic evidence for impaired redox adaptation as a convergence mechanism linking glutathione (GSH) regulation, N-methyl-D-aspartate receptor hypofunction, parvalbumin-interneuron and perineuronal-net vulnerability, mitochondrial–glial dysfunction, and neuroimmune signalling. The findings do not support a uniform oxidative abnormality across all patients or compartments: the peripheral biomarkers are heterogeneous, the group-level brain GSH magnetic resonance spectroscopy findings are largely null, and treatment-related changes vary by marker and illness phase. Beyond the established GSH–NMDA–redox–immune models, we integrate iron–lipid redox regulation as a conditional, hypothesis-generating extension and apply a deliberately conservative evidence hierarchy. Human studies more often report a lower peripheral iron and reduced or redistributed brain iron than a uniform iron excess; the plasma signals for predominantly intracellular proteins remain analytically unvalidated, and ferroptotic neuronal death has not been demonstrated. Longitudinal, sex-aware, multi-compartment, and challenge-based studies are needed to define meaningful redox subgroups; no redox- or ferroptosis-related biomarker is currently validated to guide treatment selection.Keywords
Funding Information
- Ministry of Science, Technological Development and Innovation (451-03-136/2025-03/200007)
This publication has 72 references indexed in Scilit:
- Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: an updateMetabolic Brain Disease, 2025
- Measurement of brain glutathione with magnetic Resonance spectroscopy in Schizophrenia-Spectrum disorders — A systematic review and Meta-AnalysisBrain, Behavior, and Immunity, 2023
- Efficacy and acceptability of adjunctive n‐acetylcysteine for psychotic disorders: Systematic review and meta‐analysisHuman Psychopharmacology: Clinical and Experimental, 2023
- Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of SchizophreniaMolecular Neurobiology, 2022
- Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal StudyNeurotherapeutics, 2021
- Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studiesJournal of Neural Transmission, 2019
- Quantification of glutathione in the human brain by MR spectroscopy at 3 Tesla: Comparison of PRESS and MEGA‐PRESSMagnetic Resonance in Medicine, 2016
- Meta-Analysis of Oxidative Stress in SchizophreniaBiological Psychiatry, 2013
- Redox modulation of the NMDA receptorCellular and Molecular Life Sciences, 2000
- Abnormal growth of skin fibroblasts from schizophrenic patientsPsychiatry Research, 1991